Metastatic or Locally Advanced (Agenus GOG 3028) Temp Enrollment Hold

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

Location: CPMC (San Francisco)

Please contact: ClinicalResearch@sutterhealth.org about study Agenus GOG 3028

Principal Investigator

John Chung-Kai Chan, M.D.

Co-Investigator(s)

Lejla Delic, MD 

Recruitment Status

Active, Not Recruiting

Start Date

February 26, 2020